Skip to main content

Table 4 The results of multivariate subdistribution hazard model for stage IB GAC patients

From: The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis

Characteristics

Before PSM

After PSM

HR

95%CI

p value

HR

95%CI

p value

Age

1.02

1.01–1.03

<0.001

1.01

0.99–1.04

0.281

Year

 2004–2007

Reference

  

Reference

  

 2008–2011

0.74

0.60–0.92

0.006

0.56

0.31–1.04

0.066

 2012–2015

0.71

0.55–0.89

0.004

0.86

0.47–1.56

0.611

Gender

 Female

Reference

  

Reference

  

 Male

1.32

1.06–1.65

0.013

1.92

1.04–3.54

0.037

Race

 White

Reference

  

Reference

  

 Non-White

0.99

0.81–1.22

0.941

1.04

0.59–1.84

0.881

Marital status

 Married

Reference

  

Reference

  

 Unmarried

1.14

0.93–1.40

0.222

1.16

0.65–2.07

0.621

Grade

 I/II

Reference

  

Reference

  

 III/IV

1.11

0.92–1.33

0.271

1.02

0.62–1.73

0.941

T stage

 T1

Reference

  

Reference

  

 T2a

0.81

0.39–1.66

0.552

2.18

0.53–8.94

0.282

Primary site

 Cardia/fundus

Reference

  

Reference

  

 Greater curvature/lesser curvature/body

0.48

0.38–0.62

<0.001

0.58

0.32–1.05

0.072

 Others

0.52

0.37–0.73

<0.001

0.25

0.10–0.67

0.006

 Pylorus/antrum

0.4

0.31–0.51

<0.001

0.27

0.12–0.6

0.001

Tumor size

 ≤2cm

Reference

  

Reference

  

 ≤5cm

1.06

0.86–1.32

0.611

1.51

0.86–2.64

0.152

 >5cm

1.02

0.75–1.39

0.892

1.56

0.71–3.44

0.271

RNE

 ≥16

Reference

  

Reference

  

 1–15

1.33

1.09–1.62

0.004

1.63

1.02–2.63

0.043

RNP

 0

Reference

  

Reference

  

 1

1.17

0.56–2.47

0.683

2.78

0.65–11.93

0.171

 2

1.57

0.72–3.39

0.251

1.94

0.35–10.67

0.442

Radiation

 None

Reference

  

Reference

  

 Yes

1.29

0.95–1.77

0.113

1.54

0.82–2.97

0.201

Chemotherapy

 None

Reference

  

Reference

  

 Yes

0.71

0.53–0.96

0.028

0.51

0.31-0.82

0.007